HY-0025

N/A

Report date: 2025/12/19 10:20:03

Base Information

Drug NameHY-0025
Drug Alias NameHY-0025
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsUrinary Bladder NeoplasmsUterine Cervical NeoplasmsLung Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesSichuan Huiyu Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSichuan Huiyu Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsUrinary Bladder NeoplasmsUterine Cervical NeoplasmsLung Neoplasms +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A